Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of.  | The combined company is ...

Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum ...

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching ...

Ligand Pharmaceuticals (LGND) and Channel Therapeutics (CHRO) announced the signing of a definitive merger agreement to combine Ligand’s wholly ...

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.